aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Proacta Inc. is a global biopharmaceutical company dedicated to developing hypoxia-activated drugs aimed at treating cancer. These innovative therapies specifically target cancer cells in low-oxygen environments, offering a novel approach to cancer treatment. Proacta serves the international healthcare industry, focusing on providing advanced solutions to improve patient outcomes.
Proacta has made significant strides in the biopharmaceutical field, contributing to the development of targeted cancer therapies. By concentrating on hypoxia-activated drugs, Proacta has positioned itself as a leader in this niche area of oncology. The company's efforts have the potential to transform cancer treatment and provide new hope for patients worldwide.
Operating Status
Inactive
Ownership Type(s)
Private
Main Product(s)
Pharmaceuticals
Technology
Biotech
Tags
Biotech
Geographic Exposure
Global
When was Proacta founded?
Proacta was founded in 2004.
Where is Proacta’s headquarters located?
Proacta’s headquarters is located in Los Angeles, CA, US.
When was Proacta’s last funding round?
Proacta’s most recent funding round was for $500k (USD) in December 2011.
How many employees does Proacta have?
Proacta has 5 employees as of Feb 5, 2024.
How much has Proacta raised to-date?
As of July 05, 2023, Proacta has raised a total of $47M (USD) since Dec 15, 2011.
Add Comparison
Total Raised to Date
$47M
USD
Last Update Dec 15, 2011
Last Deal Details
$500k
USD
Dec 15, 2011
Debt Financing
Total Employees Over Time
5
As of Feb 2024
Proacta Address
4275 Executive Square
Suite 440
Los Angeles,
California
92037
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts